Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Gastroenterology
Disease Category: Inflammatory Bowel Disease
Trial Information
Investigational Drug Vedolizumab (MLN0002) for Adults with Moderate to Severe Crohn’s Disease (IBD)
Researchers at the Massachusetts General Hospital Crohn’s and Colitis Center are taking part in a research study that will collect information about the long-term safety and effectiveness of an investigational drug, Vedolizumab, for the treatment of moderate to severe Crohn’s disease.
This research study is for adults diagnosed with moderate to severe Crohn’s disease who have not responded well to other drug therapies. Subjects will receive infusions (injected in the vein) of the study drug or placebo (inactive salt water) every four weeks through week 50, with the option of enrolling in a long-term trial of Vedolizumab to receive further treatment. The research study includes a Screening Visit followed by 17 visits for infusions and clinical visits with doctor. If you do not roll in to the long-term trial you will be asked to participate in a Week 66 safety visit and in long-term safety phone calls very 6 months for 2 years. Your doctor’s decision to prescribe Vedolizumab is separate from your taking part in the trial.
For more information, please contact Elisabeth Cole at ecole4@partners.org, or (617) 724-7559.
Elisabeth B Cole
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Phone: 6177247559
EMail: ecole4@gmail.com
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
